ABSTRACT
Cough is one of the most common symptoms of COVID-19 (COronaVIrus Disease-2019), occurring in more than 70% of cases. The cough associated with the new coronavirus infection tends to be non-productive and requires symptomatic antitussive therapy. However, at present, there is insufficient data on the effectiveness of various antitussive agents in COVID-19. The aim. Analysis of the clinical and economic efficiency and safety of the use of levodropropizin in comparison with standard symptomatic therapy of patients with a new coronavirus infection COVID-19 in the real-life clinical setting. Methods. An open observational multicenter study was conducted in Moscow, Krasnodar, Kazan, Voronezh, and Rostov-on-Don. The study enrolled 250 inpatient COVID 19 patients (1 875 years) with complaints of dry unproductive cough which required symptomatic treatment. The main group included 150 people who received levodropropizine according to the label. The comparison group received other antitussive drugs. Each patient was examined on days 1, 4 and 8. The examination included collection of the current complaints and medical history, physical examination and assessment of the intensity of cough using day and night cough assessment scale using a 6-point scale for assessing daytime and nighttime cough and a visual analog scale (VAS). Results. In the main group, significant differences were revealed between the baseline and Day 4 in the form of a significant decrease in the severity of daytime cough (р = 0.002);significant differences were found between Day 4 and Day 8 for both daytime (р = 0.002) and nocturnal cough (р = 0.0001). The comparison group showed positive dynamics, but significant differences were seen only between the baseline and Day 8 at night (р = 0.001). The severity of cough on VAS scale in the main group differed significantly on Day 8 as compared to baseline (р = 0.001), as well as between Day 4 and Day 8 (р = 0.002). No significant differences were seen in the comparison group. No adverse effects were observed during treatment with levodropropizine. Conclusion. Levodropropizine has shown high efficacy and safety in the treatment of dry unproductive cough in comparison with standard symptomatic therapy in the form of a significant decrease in cough intensity according to both scales, starting from the 4th day. © 2022 Medical Education. All rights reserved.
ABSTRACT
AIM: To study the dynamics and contribution of mortality from Diseases of the respiratory system (DRS) in 2019 and 2020 to mortality from all causes with and without deaths from COVID-19 in 82 regions of the Russian Federation. MATERIALS AND METHODS: The data provided by Rosstat for 2019 and 2020 on the average annual population and the number of deaths due to causes of DRS (class J00J99) were used the standardised death rate (SDR) were calculated, the regional average value, standard deviation and coefficient of variation. RESULTS: The average increase in the SDR from DRS in 2020 was 22.1913.22 per 100 thousand population (66.4489.6% higher than in 2019). The average regional SDR from DRS + COVID-19 in 2020 was higher than the SDR from DRS in 2019 by 87.6530.1 per 100 thousand population. The average regional share of SDR in the structure of mortality excluding COVID-19 increased from 3.661.44 to 5.062.49%; taking into account COVID-19, it increased to 10.963.13%. In 16 regions, the SDR from DRS + COVID-19 exceeded the increase in mortality from all causes. No correlation was found between SDR (2020) from all causes and SDR from COVID-19 (r=0.09; p=0.39); an inverse correlation was found between SDR from DRS and SDR from COVID-19 in 2020 (r=-0.42; p0.0001). CONCLUSION: Against the background of high interregional variability of SDR from DRS in most regions, an increase in the mortality rate from DRS and the contribution of DRS to total mortality in 2020 was registered.